<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184221">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695864</url>
  </required_header>
  <id_info>
    <org_study_id>SU-05222008-1180</org_study_id>
    <secondary_id>14228</secondary_id>
    <nct_id>NCT00695864</nct_id>
  </id_info>
  <brief_title>Effect of Ondansetron for Withdrawal Symptoms</brief_title>
  <official_title>Effect of Ondansetron for Withdrawal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve
      withdrawal symptoms experienced while the patient is being weaned off opioid medications.
      This medication has shown anecdotal evidence of being affective for the treatment of
      withdrawal symptoms and we hope to determine whether this is affective.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of withdrawal symptoms</measure>
    <time_frame>Duration of trial</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo - sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron and Placebo crossover</intervention_name>
    <arm_group_label>Placebo - sugar pill</arm_group_label>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:-Over 18 years of age

          -  No medical contraindications to medication

          -  Able to fulfill research procedures

        Exclusion Criteria:-Subjects who are unable to respond to our questionnaires or to stimuli
        as required by the experimental protocol will be excluded.

          -  Subjects will be excluded if they have a history of significant psychiatric disorders
             that would prevent them from engaging in a treatment program.

          -  Participating in other studies that would interfere with the procedures in this study

          -  Known or apparent pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Mackey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>January 4, 2011</lastchanged_date>
  <firstreceived_date>June 9, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Sean Mackey</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
